Major Biotechnology Company Selects OmniComm Systems to Provide eClinical Solutions for Phase I HIV Trials
FT. LAUDERDALE, Fla., Aug. 10 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a global leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a major West coast biopharmaceutical company has selected OmniComm to provide eClinical solutions for two of its phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for approximately 7 months. OmniComm Systems has already done extensive work with this client in different therapeutic areas.
"This latest contract, awarded to us by a major Biotech company reemphasizes the high value of the overall service offerings we bring to our clients," said Stephen Johnson, OmniComm's COO. "Our continued ability to provide uniquely tailored state of the art e-clinical solutions to life science companies is what distinguishes us from other EDC providers. Our products allow companies involved in clinical research, to stay competitive in the current healthcare market while significantly improving their operational efficiencies." Mr. Johnson also added, "We will continue to add products and services to our mix to not only optimize the value to our customers, but to also generate additional revenue and increase shareholder value." This explains the two recent acquisitions that OmniComm has completed acquiring the EDC assets of ERT and Logos Technologies Ltd.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Catherine Lemercier Gary Nash OmniComm Systems, Inc. CEOcast, Inc. for OmniComm 954-473-1254 Extension 283 212-732-4300 firstname.lastname@example.org email@example.com Stephen Johnson OmniComm Systems, Inc 954-377-1726
SOURCE OmniComm Systems, Inc.
You May Also Like